Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic - PubMed (original) (raw)
Review
Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic
Manuel Yepes et al. Trends Neurosci. 2009 Jan.
Abstract
Thrombolysis with tissue-type plasminogen activator (tPA) is used for the treatment of patients with acute ischemic stroke. However, a growing body of evidence indicates that, besides the unquestionable benefit from its thrombolytic activity, tPA also has a deleterious effect on the ischemic brain including cytotoxicity and increased permeability of the neurovascular unit with the development of cerebral edema. Because an increasing number of acute stroke patients are treated with tPA, it is important to know the mechanisms of harmful effects of tPA on the ischemic brain. Here, the best studied pathways of tPA neurotoxicity are discussed along with future directions for a safer use of tPA as a thrombolytic agent in the setting of acute ischemic stroke.
Similar articles
- Plasminogen activation and thrombolysis for ischemic stroke.
Medcalf RL, Davis SM. Medcalf RL, et al. Int J Stroke. 2012 Jul;7(5):419-25. doi: 10.1111/j.1747-4949.2012.00783.x. Epub 2012 Mar 30. Int J Stroke. 2012. PMID: 22463085 Review. - Recombinant tissue plasminogen activator induces blood-brain barrier breakdown by a matrix metalloproteinase-9-independent pathway after transient focal cerebral ischemia in mouse.
Copin JC, Bengualid DJ, Da Silva RF, Kargiotis O, Schaller K, Gasche Y. Copin JC, et al. Eur J Neurosci. 2011 Oct;34(7):1085-92. doi: 10.1111/j.1460-9568.2011.07843.x. Epub 2011 Sep 6. Eur J Neurosci. 2011. PMID: 21895804 - Role of tissue plasminogen activator in acute ischemic stroke.
Hatcher MA, Starr JA. Hatcher MA, et al. Ann Pharmacother. 2011 Mar;45(3):364-71. doi: 10.1345/aph.1P525. Epub 2011 Mar 8. Ann Pharmacother. 2011. PMID: 21386027 Review. - Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke.
Ning M, Furie KL, Koroshetz WJ, Lee H, Barron M, Lederer M, Wang X, Zhu M, Sorensen AG, Lo EH, Kelly PJ. Ning M, et al. Neurology. 2006 May 23;66(10):1550-5. doi: 10.1212/01.wnl.0000216133.98416.b4. Neurology. 2006. PMID: 16717217 - Treatment with melagatran alone or in combination with thrombolytic therapy reduced ischemic brain injury.
Wang CX, Ding X, Shuaib A. Wang CX, et al. Exp Neurol. 2008 Sep;213(1):171-5. doi: 10.1016/j.expneurol.2008.05.020. Epub 2008 Jun 7. Exp Neurol. 2008. PMID: 18598697
Cited by
- The Plasminogen Activation System Promotes Neurorepair in the Ischemic Brain.
Yepes M. Yepes M. Curr Drug Targets. 2019;20(9):953-959. doi: 10.2174/1389450120666181211144550. Curr Drug Targets. 2019. PMID: 30539695 Free PMC article. Review. - 12/15 Lipoxygenase as a Therapeutic Target in Brain Disorders.
Karatas H, Cakir-Aktas C. Karatas H, et al. Noro Psikiyatr Ars. 2019 Sep 5;56(4):288-291. doi: 10.29399/npa.23646. eCollection 2019 Dec. Noro Psikiyatr Ars. 2019. PMID: 31903039 Free PMC article. Review. - Safety and efficacy of alteplase in the treatment of acute ischemic stroke.
Micieli G, Marcheselli S, Tosi PA. Micieli G, et al. Vasc Health Risk Manag. 2009;5(1):397-409. doi: 10.2147/vhrm.s4561. Vasc Health Risk Manag. 2009. PMID: 19475777 Free PMC article. Review. - The pleiotropic effects of tissue plasminogen activator in the brain: implications for stroke recovery.
Grummisch JA, Jadavji NM, Smith PD. Grummisch JA, et al. Neural Regen Res. 2016 Sep;11(9):1401-1402. doi: 10.4103/1673-5374.191204. Neural Regen Res. 2016. PMID: 27857733 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources